Zai Lab Ltd (NASDAQ:ZLAB) Stake Raised by Segantii Capital Management Ltd

Segantii Capital Management Ltd raised its stake in Zai Lab Ltd (NASDAQ:ZLAB) by 1.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,330,000 shares of the company’s stock after acquiring an additional 41,112 shares during the period. Zai Lab makes up 14.6% of Segantii Capital Management Ltd’s portfolio, making the stock its biggest position. Segantii Capital Management Ltd owned approximately 5.73% of Zai Lab worth $107,726,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZLAB. Parallel Advisors LLC purchased a new stake in shares of Zai Lab during the second quarter valued at $36,000. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Zai Lab by 0.7% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 199,903 shares of the company’s stock valued at $6,971,000 after buying an additional 1,297 shares during the last quarter. Advisors Preferred LLC purchased a new stake in shares of Zai Lab during the second quarter valued at $54,000. JPMorgan Chase & Co. purchased a new stake in shares of Zai Lab during the second quarter valued at $59,000. Finally, Aperio Group LLC purchased a new stake in shares of Zai Lab during the second quarter valued at $95,000. 60.03% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts recently commented on ZLAB shares. China Renaissance Securities started coverage on Zai Lab in a research report on Wednesday, September 4th. They set a “buy” rating on the stock. Citigroup set a $65.00 price objective on Zai Lab and gave the company a “buy” rating in a research report on Wednesday, September 4th. Leerink Swann set a $48.00 price objective on Zai Lab and gave the company a “buy” rating in a research report on Wednesday, September 4th. Macquarie started coverage on Zai Lab in a research report on Friday, July 5th. They set an “outperform” rating and a $36.54 price objective on the stock. Finally, Zacks Investment Research raised Zai Lab from a “sell” rating to a “hold” rating in a research report on Saturday, September 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $42.87.

NASDAQ:ZLAB traded up $0.75 on Thursday, hitting $30.54. The stock had a trading volume of 3,100 shares, compared to its average volume of 134,917. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of -11.63 and a beta of 1.32. The business’s 50-day simple moving average is $33.27 and its two-hundred day simple moving average is $31.95. Zai Lab Ltd has a 52-week low of $15.18 and a 52-week high of $38.44.

Zai Lab Company Profile

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.

Read More: Cost of Capital Explained

Want to see what other hedge funds are holding ZLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zai Lab Ltd (NASDAQ:ZLAB).

Institutional Ownership by Quarter for Zai Lab (NASDAQ:ZLAB)

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.